End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -.--% | -.--% |
Sales 2024 * | 145M 199M | Sales 2025 * | 270M 369M | Capitalization | 1.04B 1.42B |
---|---|---|---|---|---|
Net income 2024 * | -140M -191M | Net income 2025 * | -51M -69.74M | EV / Sales 2024 * | 6.19 x |
Net cash position 2024 * | 142M 194M | Net cash position 2025 * | 115M 157M | EV / Sales 2025 * | 3.44 x |
P/E ratio 2024 * |
-7.27
x | P/E ratio 2025 * |
-20.3
x | Employees | 244 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.91% |
Latest transcript on Tarsus Pharmaceuticals, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Bobak Azamian
CEO | Chief Executive Officer | 46 | 16-12-31 |
Jeffrey Farrow
DFI | Director of Finance/CFO | 62 | 23-04-23 |
Sesha Neervannan
COO | Chief Operating Officer | 56 | 20-07-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Link
BRD | Director/Board Member | 78 | 16-12-31 |
Wendy Yarno
BRD | Director/Board Member | 68 | 20-11-18 |
Director/Board Member | 69 | 19-11-30 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.55% | 823B | |
+42.31% | 641B | |
-6.83% | 352B | |
+17.15% | 324B | |
+7.09% | 301B | |
+14.02% | 241B | |
+1.64% | 223B | |
+13.66% | 218B | |
+7.87% | 167B |